This episode examines Stanford Medicine’s identification of two distinct migraine subtypes using functional MRI that reveal severity and frequency operate independently, creating treatment gaps under current chronic classification criteria. The briefing covers the FDA’s three month extension of the lecanemab subcutaneous starting dose review to August twenty fourth, twenty twenty six, following submission of additional information constituting a major amendment. The episode concludes with analysis of research showing ultra processed food consumption correlates with cardiometabolic risk in a dose response relationship, suggesting disruption in biological signaling pathways extends beyond calorie excess or nutrient imbalance and implicates gut microbiome communication networks in metabolic regulation.
